Clinical trials in rare lymphomas

The table below shows a list of The Lymphoma Group's current clinical trials open for recruitment for rare lymphomas such as:

  • Mantle cell lymphoma
  • Burkitt's lymphoma
  • MALToma (Marginal zone) lymphoma
  • CNS (brain) lymphoma

If you would like to know how to access our trials please click here

 

Trial name

 

Description

 

Click for more information (external page)

 

AZD3965

 

Phase 1 trial looking at a new treatment called AZD3965.

Suitable for patients with Burkitt lymphoma or DLBCL which has come back after previous treatment

 

 

BI 1206 CRUK CD32b

 

Phase 1/2a study looking at blocking the CD32b protein with the antibody BI 1206.

Suitable for patients with various rare lymphoma types which have come back after previous treatment

 

 

 

ENRICH

 

A phase 2/3 trial looking at treatment options for people over 60 with mantle cell lymphoma who are unable to have a stem cell transplant

Suitable for patients with mantle cell lymphoma who haven’t yet received any treatment

 

 

 

JCAR017

 

Phase 2 study determining efficacy and safety of JCAR017.

Suitable for patients with PCNSL, CNS involved lymphoma, Richter's transformation, and DLBCL which has come back after previous treatment

 

 

 

RIVA

 

A phase 2 trial testing the combination of rituximab and varlilumab.

Suitable for patients with various rare lymphoma types which have come back after previous treatment

 

 

 

PCYC- 1143

 

Phase 3 study looking at Ibrutinib with Venetoclax in patients with Mantle Cell lymphoma.

Suitable for patients with mantle cell lymphoma which has come back after previous treatment

 

 

 

TIER

 

Phase 1-2 trial to find the best dose and test the safety and effectiveness of the TIER regimen of chemotherapy and rituximab.

Suitable for patients with CNS (brain) lymphoma which has come back after previous treatment

 

 

 

MCL Biobank

 

Non medicinal (observational) study suitable for patients with a recent diagnosis of mantle cell lymphoma.

 

 

 

*Please note, we update this page fortnightly

With special thanks to the following: